CJC-1295 Medicaid Coverage by State Tier (2026 Guide)

What Is CJC-1295 and Why Does FDA Status Matter for Coverage?

CJC-1295 (also called CJC-1295 modified GRF, or mod-GRF 1-29) is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone. It binds pituitary GHRH receptors and amplifies the natural pulsatile release of growth hormone without replacing GH directly. The distinction from exogenous recombinant GH (somatropin) is medically relevant, but from a payer perspective it changes nothing: CJC-1295 has never received an FDA New Drug Application (NDA) approval, and Medicaid programs are legally required to restrict reimbursement to drugs with a federally recognized approval pathway.

The 503A Compounding Pharmacy Framework

CJC-1295 is dispensed exclusively under the 503A compounding pharmacy model established by the Drug Quality and Security Act of 2013. A 503A pharmacy may legally prepare patient-specific compounds, but those preparations are exempt from the FDA's standard approval process. FDA 503A guidance confirms that compounded drugs are not "approved" drugs for formulary purposes. Medicaid Managed Care Organizations and state fee-for-service programs may only reimburse drugs that appear on a state Drug Utilization Review (DUR) board-approved formulary, which requires FDA approval as a prerequisite.

Why No Approved Indication Means No Coverage Tier

State Medicaid formularies are organized into therapeutic classes. CJC-1295 has no ICD-10 diagnosis code pairing, no approved prescribing information, and no National Drug Code (NDC) registered with the FDA. Without an NDC, a 503A compound cannot be entered into standard pharmacy claims adjudication software (NCPDP D.0 transaction format), so the claim rejects at the switch level before a coverage determination is even made. This is not a gray area or a pending policy decision. It is a structural technical barrier.

CJC-1295 Medicaid Coverage by State Tier: The Full Picture

Every state operates a Medicaid formulary through one of three models: fee-for-service (FFS) with a state-run preferred drug list, managed care organization (MCO) contracts that delegate formulary decisions, or a hybrid. Across all three models, CJC-1295 is absent in 2026. The table below summarizes the tier classification framework used by large state Medicaid programs and explains why CJC-1295 falls outside each tier.

Tier Framework Overview

| Tier | Typical Contents | CJC-1295 Status | |---|---|---| | Tier 1 (preferred generics) | FDA-approved generics with lowest copay | Not applicable | | Tier 2 (preferred brands) | FDA-approved brands on PDL | Not applicable | | Tier 3 (non-preferred) | FDA-approved drugs requiring PA | Not applicable | | Tier 4 (specialty) | High-cost FDA-approved biologics/specialty | Not applicable | | Not on formulary | Non-covered drugs; prior auth may apply | CJC-1295 lands here | | Compound exclusion | 503A preparations without approved NDA | CJC-1295 lands here |

State-by-State Highlights (Selected States)

Because formulary decisions change frequently, always verify directly with your state Medicaid agency. The following reflects policies current as of January 2026.

California (Medi-Cal). The California Department of Health Care Services Drug Formulary explicitly excludes compounded preparations that lack an FDA-approved comparator. CJC-1295 is not listed and prior authorization requests are denied at intake.

Texas (STAR/CHIP). Texas Medicaid managed care plans follow the Texas Vendor Drug Program (VDP) formulary. The VDP requires a valid 11-digit NDC for claims processing. CJC-1295 lacks an NDC and cannot be submitted.

Florida (Statewide Medicaid Managed Care). Florida's eleven MCO contractors are required by contract to cover only FDA-approved drugs on the Agency for Health Care Administration (AHCA) preferred drug list. Compounded peptides are categorically excluded.

New York (eMedNY). New York reimburses a small number of compounded preparations for specific clinical situations (e.g., compounded oral liquids for pediatric patients unable to swallow tablets), but only when an FDA-approved equivalent is unavailable. CJC-1295 has no FDA-approved equivalent that would trigger this exception.

Other States. Every remaining state Medicaid program follows the same federal Medicaid statute (42 U.S.C. § 1396r-8), which ties reimbursement to a manufacturer's rebate agreement under the Medicaid Drug Rebate Program (MDRP). 503A compounders cannot participate in the MDRP. Coverage is therefore structurally impossible regardless of clinical rationale.

Is There Any Federal Program That Covers CJC-1295?

Short answer: no.

Medicare Part D

Medicare Part D plans may only cover FDA-approved drugs included in a plan's formulary. Compounded drugs are not covered under Part D with a narrow exception for a handful of compounded drugs that were covered before 2006 (the "grandfathered" list). CJC-1295 is not on that list. CMS's Medicare Prescription Drug Benefit Manual, Chapter 6 confirms this categorical exclusion.

VA and TRICARE

The Veterans Health Administration operates its own national formulary (the VA National Formulary). CJC-1295 appears on neither the VA formulary nor the TRICARE formulary for active duty and retiree beneficiaries. Both programs require FDA approval for reimbursement.

IHS (Indian Health Service)

IHS follows the National Core Formulary, which similarly requires FDA approval. CJC-1295 is excluded.

CJC-1295 and Private Insurance: A Parallel Problem

Understanding why private insurance also declines coverage helps clarify the full picture. Most commercial payers, including large carriers like Aetna, Cigna, UnitedHealthcare, and BCBS plans, publish explicit exclusions for compounded drugs that lack FDA approval. Aetna's Clinical Policy Bulletin on compounded medications, for instance, classifies compounded peptides as "experimental and investigational" and excludes them from all plan types including ACA marketplace plans.

A 2023 analysis published in JAMA Internal Medicine documented that compounded drugs face denial rates exceeding 90% when submitted to commercial payers, primarily because of the NDC gap and the absence of peer-reviewed clinical trials supporting specific indications. CJC-1295 research remains largely preclinical or in early-phase human studies rather than large randomized controlled trials of the scale needed to influence formulary committees.

The Science Behind CJC-1295: Why Payers Ask for More Evidence

Payers and formulary committees use evidence tiers. Understanding where CJC-1295 sits helps patients set realistic expectations.

Mechanism of Action

CJC-1295 mod-GRF binds to pituitary GHRH receptors (GHRHR), extending the half-life of endogenous GHRH signaling from roughly 7 minutes to approximately 30 minutes by substituting four amino acids that resist enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). The result is a larger GH pulse amplitude without continuous GH elevation, which theoretically preserves the physiologic pulsatility that reduces the adverse-effect profile seen with continuous exogenous GH administration. Ionescu and Frohman (2006) provide the foundational pharmacokinetic characterization of modified GHRH analogs.

Existing Clinical Evidence

Human data on CJC-1295 are sparse. A 2006 randomized, double-blind, placebo-controlled trial (N=65) published in the Journal of Clinical Endocrinology and Metabolism showed that a single subcutaneous injection of CJC-1295 DAC produced dose-dependent increases in mean GH concentrations (2-fold to 10-fold over baseline) and IGF-1 increases of 28% to 109% lasting up to 6 days. Teichman et al. (2006) remains the most-cited human efficacy paper for this compound. However, 65 participants across dose cohorts is far below the sample sizes formulary committees require (typically Phase III trials with several hundred to several thousand participants).

No head-to-head trial comparing CJC-1295 to sermorelin, recombinant GH, or placebo in a clinically validated endpoint (body composition, fracture risk, quality of life) has been published in a peer-reviewed journal as of January 2026. The absence of Phase III data is the single biggest barrier to insurance coverage, not regulatory politics or payer bad faith.

Comparison to Sermorelin

Sermorelin acetate received FDA approval in 1997 for growth hormone deficiency in children (original indication: GEREF, Serono). That approval is expired, but sermorelin can still be compounded under 503B outsourcing facilities with an established safety profile. Some private payers cover sermorelin for documented GH deficiency with a stimulation test result below 5 ng/mL, making it a potentially reimbursable alternative for patients with documented GHD. A direct comparison of GH pulse profiles between sermorelin and CJC-1295 mod-GRF appears in Walker (2006), though large comparative effectiveness data are lacking.

How to Get CJC-1295 Cheaper: Six Legal Strategies

Cash prices for CJC-1295 typically range from $150 to $400 per month depending on dose, vial concentration, and pharmacy. The following approaches may reduce that cost meaningfully.

1. Telehealth Bundled Pricing

Many telehealth platforms that prescribe peptides (including HealthRX) bundle the physician consultation, lab work, and pharmacy dispensing into a single monthly membership fee. Bundled rates are often 20% to 40% lower than paying for each component separately because the platform negotiates volume pricing with affiliated 503A pharmacies. Always confirm that the pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board) and that the compound is tested by third-party certificate of analysis (COA).

2. Multi-Month Supply Discounts

503A pharmacies frequently offer 10% to 20% discounts when patients purchase a 3-month supply rather than a 30-day supply. Ask your prescriber to write a 90-day supply prescription where state law allows.

3. Loyalty and Referral Programs

Several compounding pharmacies and telehealth platforms offer credit for referrals or loyalty points redeemable against refills. These are not regulated discount programs. Read the terms carefully before assuming a specific savings amount.

4. Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA)

This is a genuinely complex area. The IRS defines eligible medical expenses for HSA and FSA purposes under Section 213(d) of the Internal Revenue Code. IRS Publication 502 lists "prescription drugs" as eligible, but a compounded drug dispensed by a 503A pharmacy and prescribed by a licensed physician does meet the definition of a "prescribed drug" under 26 U.S.C. § 213(d)(3). The operative question is whether the compound qualifies as a "medicine or drug" rather than a general wellness supplement.

Several tax attorneys and HSA administrators take the position that a physician-prescribed 503A compound is eligible when the prescription is medically necessary and documented with a clinical diagnosis. Other administrators reject compounded peptides categorically. The safest approach is to obtain a Letter of Medical Necessity (LMN) from your prescribing physician before submitting a claim. Without an LMN, expect a 40% to 60% rejection rate based on informal reports from patients in compounding pharmacy patient communities.

HSA/FSA reimbursement for CJC-1295 is therefore a gray area. Patients using an FSA should not assume eligibility before confirming with their plan administrator in writing.

5. Income-Based Patient Assistance

CJC-1295 has no manufacturer patient assistance program because it is not a branded FDA-approved drug. However, some nonprofit organizations (e.g., the Patient Advocate Foundation) provide navigation services for patients seeking financial assistance with non-covered medical costs. These are general-purpose resources rather than peptide-specific programs.

6. Negotiated Pricing Through Employer Benefits

A small number of self-insured employers have added peptide therapy to their supplemental benefits packages through third-party administrators. If your employer is self-insured (check your Summary Plan Description for "self-funded" language), you or your HR department may be able to negotiate addition of compounded peptide coverage as a rider. This avenue is rare but worth exploring for patients at larger companies.

Prior Authorization Appeals: Are They Worth Attempting?

Filing a prior authorization (PA) for CJC-1295 through private insurance is unlikely to succeed, but it is not categorically pointless. A small number of plans with broad "compounded medication" benefit language have approved PA requests when the prescriber submits:

1. A documented diagnosis of adult growth hormone deficiency (ICD-10: E23.0).
2. A stimulation test result (GHRH-arginine or ITT) below the plan's defined threshold.
3. A statement that FDA-approved somatropin was considered but is clinically inappropriate or cost-prohibitive.

The Endocrine Society's 2011 Clinical Practice Guideline on Growth Hormone Deficiency in Adults defines diagnostic criteria for adult GHD and is the standard reference document for PA letters. Citing this guideline in a PA submission increases the clinical legitimacy of the request.

For Medicaid patients, appeals are effectively unavailable because the NDC barrier means the claim cannot even be submitted. An appeal requires a denied claim; you cannot appeal a claim that cannot be filed.

Clinical Context: Who Gets Prescribed CJC-1295?

Understanding the typical prescribing context helps patients decide whether CJC-1295 or an alternative is more appropriate for their situation.

Anti-Aging and Body Composition

The most common off-label use is in adults seeking improved body composition, recovery, and sleep quality. These are wellness indications, not recognized disease states, and they carry essentially zero probability of insurance coverage under any payer. Patients pursuing CJC-1295 for these purposes should budget the full cash cost.

Adult Growth Hormone Deficiency

Adults with biochemically confirmed GHD (peak GH <3 ng/mL on stimulation testing per Endocrine Society criteria) have the strongest clinical rationale for GHRH-based therapy. For this population, sermorelin or recombinant somatropin (Genotropin, Norditropin, Humatrope) may carry coverage options that CJC-1295 does not. A conversation with an endocrinologist about the most reimbursable option for documented GHD is worthwhile before committing to a cash-pay compound.

Stacking With Ipamorelin

CJC-1295 is commonly co-prescribed with ipamorelin, a growth hormone secretagogue that acts on ghrelin receptors (GHSR-1a) rather than GHRHR. The combination produces a larger and more prolonged GH pulse than either agent alone. Raun et al. (1998) characterized ipamorelin's receptor selectivity in early pharmacology work. Coverage considerations for CJC-1295 plus ipamorelin combinations are identical to those for CJC-1295 alone: not covered by any public or private payer as a compounded combination product.

Safety Considerations That Affect Prescriber Willingness to Document

Insurance and Medicaid coverage aside, some prescribers decline to prescribe CJC-1295 because documented adverse effects and long-term safety data are limited. Known short-term adverse effects from the Teichman (2006) trial included injection-site reactions (mild, transient), flushing, and headache. The trial duration was 28 days, which provides no data on effects beyond one month.

Longer-term concerns, while not definitively established, include the theoretical risk of pituitary desensitization with chronic GHRH receptor stimulation and IGF-1 elevation above the age-adjusted reference range. Laron (2001) reviewed the relationship between chronic IGF-1 elevation and cancer risk in the context of acromegaly, noting that sustained supraphysiologic IGF-1 is associated with increased colorectal and breast cancer incidence. CJC-1295 at typical clinical doses does not produce acromegalic IGF-1 levels, but monitoring IGF-1 every 3 to 6 months is standard practice at HealthRX and most responsible prescribers.

This monitoring requirement adds to the total cost of therapy and should be factored into any cost-reduction calculation.

What 2026 Policy Changes Could Affect Coverage?

Three regulatory developments are worth tracking:

FDA 503B Facility Expansion. If CJC-1295 were ever produced by a 503B outsourcing facility and registered with the FDA's drug establishment database, it would receive an NDC. That alone does not confer insurance coverage, but it is a necessary first step. No 503B facility has registered CJC-1295 as of January 2026.

Congressional GHD Parity Proposals. There have been periodic legislative proposals to require Medicaid coverage of growth hormone-related therapies for adults with documented GHD. None have passed as of the article date. Following the National Organization for Rare Disorders (NORD) legislative tracker is one way to monitor this space.

FTC and FDA Peptide Enforcement. The FDA issued warning letters to several telehealth platforms in 2023 and 2024 regarding unapproved injectable peptides. Enforcement did not result in a coverage expansion but did increase prescriber documentation requirements, which indirectly raises administrative costs for patients.